ArticleFrontiers in cellular and infection microbiology2026
Clinical characteristics of hospitalized children with mycoplasma pneumoniae pneumonia in Chinese tertiary hospitals during the 2023-2024 post-pandemic period.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of an early warning score for refractoryTranslational pediatrics · 2026Article
- Etiology and Epidemiology of Acute Lower Respiratory Infections Among Hospitalized Pediatric Patients in Northeastern China: A Retrospective Study from 2023 to 2025.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: The COVID-19 pandemic and subsequent non-pharmaceutical interventions (NPIs) altered the epidemiological patterns of Methods: A retrospective analysis was conducted on 1342 hospitalized children with MPP from January 2023 to December 2024 in Shenzhen Hospital of Southern Medical University, China. MPP, macrolide-unresponsive MPP (MUMPP), and severe MPP (SMPP) were diagnosed according to predefined criteria. Differences between mutated MPP and MUMPP were investigated, and risk factors for MUMPP, SMPP and mixed infection were assessed. Results: MPP exhibits a bimodal temporal distribution in 2023-2024, with the first peak occurring in November 2023, and the second smaller peak in August 2024. The macrolide resistance gene positive rate was 86.43% (121/140), but only 64.29% (90/140) were clinically unresponsive to macrolides ( Conclusions: This study highlights the complex epidemiological and clinical landscape of MPP in the post-pandemic era. The discordance between macrolide resistance genes and clinical treatment suggests that macrolides may still be effective in some cases. The identified risk factors and clinical features provide valuable insights for optimizing treatment strategies and managing pediatric MPP in the post-pandemic context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.